The recognition of these serious adverse effects sparked interest in CsA-sparing strategies [8]: dose reduction is associated with a modest improvement in renal function, but CsA-induced nephropathy is progressive over time when exposure is maintained; CsA avoidance is associated with high acute rejection rates and is not an option; minimization protocols are the current preferred therapy, including the conversion from CsA to other drugs, especially sirolimus (SRL), an inhibitor of the mammalian target of rapamycin (mTOR) [9–11]. The gene discussed is MTOR; the disease is kidney disorder.